查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018089

患者血液管理市場：按產品類型、治療方法、應用和最終用戶分類－2026-2032年全球市場預測

Patient Blood Management Market by Product Type, Therapy Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，患者血液管理市場價值將達到 183 億美元，到 2026 年將成長至 195.9 億美元，到 2032 年將達到 322.2 億美元，年複合成長率為 8.41%。

主要市場統計數據
基準年 2025 183億美元
預計年份：2026年 195.9億美元
預測年份 2032 322.2億美元
複合年成長率 (%) 8.41%

全面實施病患血液管理，以臨床優先事項、供應彈性和技術促進因素為框架，推動圍手術全期安全和組織策略。

患者血液管理正逐漸發展成為一項跨學科的必要環節，它融合了手術全期護理、輸血醫學、供應鏈管理以及以價值主導的臨床結果。該領域優先考慮的是最大限度地減少異體血液暴露、最佳化止血以及使治療性介入與患者的特定風險狀況相匹配。隨著醫院和專科醫療中心不斷適應日益複雜的手術流程以及對安全性和成本監管的加強，患者血液管理實踐在臨床管治和品質改進方面變得日益重要。

對變革性的臨床、技術和營運變化進行詳細分析，這些變化將重新定義所有醫療保健機構中的患者血液管理實踐和採購重點。

目前血液管理格局正受到多種因素的共同影響而重塑，這些因素正在重新定義臨床路徑和籌資策略策略。自體輸血系統和血液成分分離器的技術成熟，使得自體血液的再利用更加安全，並減少了對外部血液供應的依賴。同時，新一代凝血監測系統和照護現場技術支持更快速、更實證的術中介入。這些進步正促使手術全期決策更加精準，並提升即時數據在指導輸血實務中的作用。

本文詳細探討了近期關稅措施如何影響整個病患血液管理生態系統的供應鏈韌性、籌資策略、製造局部化和臨床部署模式。

關稅政策的變化會對醫療設備和耗材的整個供應鏈產生連鎖反應，進而影響醫院、專科醫療中心和經銷商的採購決策。關稅導致關鍵零件和成品進口成本上升，可能會推高自體輸血系統、凝血監測儀、止血裝置以及醫療機構一次性用品的採購成本。這種變化將迫使供應鏈管理者重新評估其籌資策略，評估總體擁有成本，並優先考慮擁有多元化製造地或本地生產能力的供應商。

全面的細分洞察揭示了產品分類、治療方法、臨床應用和醫療保健環境如何相互作用，從而塑造產品引入途徑和商業化策略。

深入的市場區隔揭示了臨床需求、技術適用性和購買行為之間的交集，從而能夠在產品、治療方法、應用和最終用戶等各個維度上製定針對性策略。按產品類型分類，市場包括抗纖溶藥物、自體輸血系統、血液成分分離系統、血液管理拋棄式產品、凝血監測系統、止血劑和密封劑以及血液容量擴充劑。在血液管理拋棄式產品中，重點在於細胞洗滌試劑盒、血液收集容器和過濾裝置。同時，凝血監測又細分為臨床實驗室分析儀和照護現場(POC) 設備，止血劑和密封劑則進一步細分為密封劑系統和局部止血劑。每個產品類型都有其獨特的市場推廣曲線，其促進因素包括臨床證據、易用性、耗材成本效益以及與手術全期工作流程的整合。

對美洲、歐洲、中東和非洲以及亞太地區的區域醫療保健系統、報銷模式和法規環境如何影響患者血液管理的實施進行策略分析。

區域趨勢影響臨床實務模式、採購偏好和監管應對措施，在主要地區形成了不同的應用路徑。在美洲，醫療保健系統的多元化發展，從大規模綜合醫院網路到門診手術中心的激增，都催生了對高階整合系統和攜帶式即時檢測解決方案的需求。此外，在成本效益數據直接影響採購決策的環境下，報銷模式和私人保險公司的影響正在加速實證患者血液管理（PBM）干預措施的推廣應用。

權威概述了全球製造商、利基創新者和區域供應商如何透過臨床證據、供應彈性和夥伴關係主導的商業化在血液管理領域競爭。

競爭格局由多元化的全球製造商、專業的醫療設備創新企業和靈活的區域供應商組成，它們各自奉行強調臨床證據、服務交付和供應鏈韌性的策略。成熟的醫療設備製造商利用其豐富的產品系列，提供整合自體輸血系統、凝血監測平台和一次性產品的整合解決方案。同時，小規模的創新企業通常專注於利用特定技術來應對特定的臨床挑戰，例如先進的密封劑、一次性過濾系統或快速照護現場分析儀。

為高階主管和臨床領導者提供實用建議，以協調證據產生、供應多樣化、定價柔軟性和個人化實施策略，從而在患者血液管理方面取得永續的成功。

產業領導者應優先考慮協作方式，將臨床證據的取得與適應性強的供應鏈策略和經營模式結合，以適應不同的醫療機構環境。投資於嚴謹的臨床研究，以證明治療效果和手術效率的提升，有助於證明醫療設備和治療方法的引入是合理的，即使在預算緊張的情況下也是如此。同樣重要的是，彈性價格設定和合約方案，以反映整體擁有成本，並使醫院能夠以最小的前期投資試用新技術。

透明嚴謹的調查方法結合了專家訪談、臨床指南整合、細分市場映射和檢驗研討會，以支持策略洞察，而無需依賴專有的市場量化。

本研究途徑整合了多個資料流和專家檢驗，以確保研究結果的可靠性、臨床相關性和可操作性。主要資訊來源包括對心臟外科、創傷科、腫瘤科和婦產科臨床負責人的深度訪談，以及與採購專家、生物醫學工程師和醫院高級管理人員的討論，從而收集關於技術推廣應用促進因素和障礙的跨職能觀點。這些定性研究結果與二手文獻、臨床指南、監管文件和同行評審的研究進行交叉比對，以檢驗臨床結論和技術性能。

一項權威的綜合分析證實，整合臨床創新、採購靈活性和供應彈性對於在所有醫療保健環境中最大限度地發揮患者血液管理的潛力至關重要。

上述研究結果凸顯了一個明確的策略需求：病患血液管理不再只是臨床上的附帶問題，而是手術全期卓越醫療、供應鏈韌性和價值醫療的核心要素。自體輸血、凝血監測、止血劑和一次性醫療設備的進步，使臨床醫生能夠減少對異體輸血的依賴，並提供針對個別患者風險狀況的個人化干涉措施。同時，採購經理和製造商必須應對價格壓力、供應鏈重組以及維持技術應用所需的強大臨床證據等挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 病人血液管理市場：依產品類型分類

  • 抗纖溶藥物
  • 自體輸血系統
  • 血液成分分離系統
  • 血液管理用拋棄式產品
    • 細胞清洗套件
    • 血液採集容器
    • 過濾裝置
  • 凝血監測系統
    • 臨床檢測設備
    • 即時檢測設備
  • 止血劑和密封劑
    • 密封系統
    • 局部止血劑
  • 血液容積擴張劑

第9章 依治療方法分類的患者血液管理市場

  • 異體輸血
  • 自體輸血
  • 細胞收集
  • 止血管理
    • 抗纖溶治療
    • 局部止血療法
  • 手術全期血液保存
    • 術中技術
    • 術後護理
    • 術前最佳化

第10章 病人血液管理市場：依應用分類

  • 心血管外科
    • 主動脈手術
    • 冠狀動脈繞道手術手術
    • 瓣膜置換術
  • 已安排的手術
  • 產科
  • 腫瘤治療
    • 化療
    • 放射治療
  • 創傷

第11章 病人血液管理市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 醫院
  • 專業醫療中心
    • 癌症治療中心
    • 心臟護理中心
    • 創傷中心

第12章 病人血液管理市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：病患血液管理市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 病人血液管理市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國病患血液管理市場

第16章：中國病患血液管理市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Baxter International Inc.
  • BioMerieux SA
  • CSL Limited
  • Danaher Corporation
  • Fresenius Kabi AG
  • Grifols, SA
  • Haemonetics Corporation
  • LivaNova PLC
  • Macopharma SA
  • Octapharma AG
  • Roche Diagnostics International AG
  • Terumo Corporation
  • ZOLL Medical Corporation
Product Code: MRR-0372549B1FF1

The Patient Blood Management Market was valued at USD 18.30 billion in 2025 and is projected to grow to USD 19.59 billion in 2026, with a CAGR of 8.41%, reaching USD 32.22 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.30 billion
Estimated Year [2026] USD 19.59 billion
Forecast Year [2032] USD 32.22 billion
CAGR (%) 8.41%

An integrative introduction to patient blood management that frames clinical priorities, supply resilience, and technological enablers driving perioperative safety and institutional strategy

Patient blood management is evolving into a cross-disciplinary imperative that intersects perioperative care, transfusion medicine, supply chain stewardship, and value-driven clinical outcomes. The field prioritizes minimizing exposure to allogeneic blood, optimizing hemostasis, and aligning therapeutic interventions with patient-specific risk profiles. As hospitals and specialty centers navigate growing procedural complexity and heightened scrutiny over safety and costs, PBM practices are increasingly central to clinical governance and quality improvement agendas.

Clinicians, administrators, and supply chain leaders now view PBM through multiple lenses: clinical efficacy, procedural efficiency, and resilience against disruptions to blood availability. Advances in point-of-care coagulation monitoring and autologous technologies enable more precise intraoperative decision-making, while innovations in hemostats, sealants, and disposable systems support safer surgical pathways. These technological shifts are complemented by evolving clinical protocols that emphasize preoperative optimization and postoperative conservation, making PBM both a clinical and organizational priority.

Moreover, patient-centric care models are reframing how therapeutic choices are communicated and implemented. Shared decision-making around transfusion thresholds, alternatives such as cell salvage or antifibrinolytic therapy, and the integration of perioperative optimization protocols underscore a broader cultural shift in hospitals and specialty centers. In this context, PBM becomes an instrument for clinical excellence, operational resilience, and measurable improvements in patient outcomes.

A detailed analysis of the transformative clinical, technological, and operational shifts redefining patient blood management practices and procurement priorities across care settings

The landscape of blood management is being reshaped by multiple converging forces that redefine clinical pathways and procurement strategies. Technological maturation in autotransfusion systems and blood component separation devices enables safer reuse of autologous blood and reduces dependency on external supply, while next-generation coagulation monitoring systems and point-of-care diagnostics support faster, evidence-based intraoperative interventions. These advances increase the granularity of perioperative decision-making and elevate the role of real-time data in guiding transfusion practices.

Simultaneously, the development and wider adoption of hemostats, sealant systems, and topical agents have transformed how surgical bleeding is managed across specialties. Improved formulations and delivery mechanisms reduce surgical time and transfusion needs, and when combined with antifibrinolytic agents and volume expanders, they support more conservative transfusion strategies. This clinical evolution dovetails with operational trends toward bundled payments and value-based procurement, incentivizing hospitals to demonstrate outcomes-driven use of PBM tools.

Finally, the strategic shift toward decentralized care and growth of ambulatory surgical centers is prompting manufacturers and suppliers to adapt product design and service models for varied care settings. Point-of-care devices engineered for speed and portability, alongside disposable-focused solutions, are increasingly relevant as care migrates out of traditional inpatient environments. As a result, stakeholders must balance innovation adoption with training, interoperability, and long-term clinical evidence to fully realize the benefits of these transformative shifts.

An in-depth exploration of how recent tariff actions affect supply chain resilience, procurement strategy, manufacturing localization, and clinical adoption patterns across the patient blood management ecosystem

Changes in tariff policy can reverberate across the supply chain for medical devices and consumables, altering procurement calculus for hospitals, specialty centers, and distributors. When tariffs increase import costs for key components or finished devices, healthcare providers may encounter higher acquisition costs for autotransfusion systems, coagulation monitors, hemostats, and disposables. This shift compels supply chain leaders to reassess sourcing strategies, evaluate total cost of ownership, and prioritize suppliers with diversified manufacturing footprints or localized production capabilities.

Beyond immediate pricing effects, tariff-driven adjustments influence long-term supplier strategies. Manufacturers may accelerate localization of critical production, invest in regional manufacturing hubs, or modify product portfolios to reduce exposure to vulnerable supply corridors. Such moves can improve resilience over time but may require near-term capital expenditure that affects pricing dynamics. For providers, the consequence is a renewed emphasis on procurement agility: multi-supplier contracting, inventory optimization, and longer-term purchasing agreements with flexibility clauses become important tools to mitigate volatility.

Clinically, higher device or disposable costs could influence adoption curves for certain technologies unless providers can clearly link them to improved outcomes or operational efficiencies. Therefore, demonstrating clinical and economic value through robust evidence becomes essential to sustain adoption. Finally, regulatory oversight and customs compliance complexities introduced by new tariff regimes can increase administrative burden, encouraging healthcare organizations to invest in compliance capabilities and to partner more closely with suppliers to streamline cross-border logistics and maintain uninterrupted access to critical PBM products.

Comprehensive segmentation insights revealing how product classes, therapeutic approaches, clinical applications, and care settings interact to shape adoption pathways and commercialization strategies

Insightful segmentation illuminates where clinical need, technology fit, and purchasing behavior intersect, enabling targeted strategies across product, therapy, application, and end-user dimensions. Based on product type, the landscape includes antifibrinolytics, autotransfusion systems, blood component separation systems, blood management disposables, coagulation monitoring systems, hemostats and sealants, and volume expanders; within blood management disposables the focus extends to cell washing kits, collection reservoirs, and filtration devices, while coagulation monitoring is distinguished by laboratory analyzers and point-of-care devices and hemostats and sealants break down into sealant systems and topical hemostats. Each product category follows its own adoption arc, driven by clinical evidence, ease of use, consumable economics, and integration with perioperative workflows.

Considering therapy type, the framework spans allogeneic transfusion, autologous transfusion, cell salvage, hemostasis management, and perioperative blood conservation; the hemostasis management domain further divides into antifibrinolytic therapy and topical hemostats therapy, and perioperative blood conservation encompasses intraoperative techniques, postoperative care, and preoperative optimization. Therapy-focused segmentation reveals where clinical protocols and multidisciplinary teams can most effectively reduce transfusion exposure and improve outcomes, with perioperative optimization often serving as the nexus between preoperative assessment and intraoperative technology utilization.

Application-based segmentation highlights cardiovascular surgery, elective surgery, obstetrics, oncology treatments, and trauma; within cardiovascular surgery the clinical complexity varies across aortic surgery, coronary artery bypass grafting, and valve replacement procedures, while oncology treatments are differentiated by chemotherapy and radiotherapy contexts. These clinical settings dictate distinct PBM priorities: elective surgery programs often emphasize preoperative optimization and intraoperative hemostatic control, trauma care stresses rapid access to point-of-care coagulation data and blood component separation, and oncology care requires coordinated strategies to manage bleeding risk during complex treatment regimens.

From an end-user perspective, adoption patterns span ambulatory surgical centers, clinics, hospitals, and specialty centers; specialty centers are further categorized into cancer treatment centers, cardiac care centers, and trauma centers. Each care setting imposes different requirements for device footprint, training intensity, consumable logistics, and reimbursement sensitivity. Ambulatory environments prioritize compact, easy-to-use devices with streamlined disposables, whereas tertiary hospitals and specialty centers demand scalable systems that can integrate with intensive care workflows and support high-volume, high-acuity cases. Understanding these segmentation dynamics is essential for product positioning, evidence generation, and tailored commercial strategies that resonate with clinicians and procurement stakeholders alike.

A strategic examination of how regional healthcare structures, reimbursement models, and regulatory environments in the Americas, Europe Middle East & Africa, and Asia-Pacific drive differentiated patient blood management adoption

Regional dynamics influence clinical practice patterns, procurement preferences, and regulatory navigation, producing distinct pathways to adoption across major geographies. In the Americas, healthcare systems vary from large integrated hospital networks to a proliferation of ambulatory surgical centers, creating demand for both high-end integrated systems and portable point-of-care solutions; reimbursement paradigms and private payer influences also accelerate adoption of evidence-backed PBM interventions in settings where cost-effectiveness data can be translated directly into procurement decisions.

In Europe, Middle East & Africa, a diverse regulatory and reimbursement landscape leads to differentiated adoption curves. Western European health systems with centralized procurement and strong emphasis on clinical guidelines often favor technologies backed by robust clinical data and long-term outcome studies, while emerging markets in the region are driven by affordability, modular solutions, and partnerships that enable local training and supply resilience. Regulatory harmonization efforts and regional procurement initiatives can both enable and constrain market entry depending on compliance alignment and certification pathways.

Across Asia-Pacific, rapid expansion of procedural volumes and ongoing investments in hospital infrastructure create opportunities for accelerated adoption of PBM technologies. Variations in healthcare financing and provider capabilities shape demand for scalable devices, consumable-efficient disposables, and cost-effective hemostatic solutions. In many markets across the region, localization of manufacturing and strategic partnerships with domestic distributors optimize cost structures and facilitate faster implementation, particularly in tertiary and specialty centers that are expanding surgical and oncology services. Overall, regional strategies must reconcile local regulatory requirements, healthcare financing models, and provider practice patterns to succeed.

An authoritative overview of how global manufacturers, niche innovators, and regional suppliers compete through clinical evidence, supply resilience, and partnership-driven commercialization in blood management

The competitive landscape is composed of diversified global manufacturers, specialized device innovators, and nimble regional suppliers, each pursuing strategies that emphasize clinical evidence, service delivery, and supply resilience. Established device companies leverage broad product portfolios to offer integrated solutions that bundle autotransfusion systems, coagulation monitoring platforms, and disposables, while smaller innovators often target specific clinical pain points with focused technologies such as advanced sealants, single-use filtration systems, or rapid point-of-care analyzers.

Strategic behaviors among companies include investment in clinical evidence generation, expansion of distribution channels, and collaborative arrangements with clinical centers to pilot new technologies. Partnerships with hospitals and specialty centers for real-world evidence collection strengthen value propositions and facilitate guideline inclusion. Meanwhile, supply chain integration and manufacturing diversification are important differentiators, with companies seeking regional production sites or multi-sourcing models to limit exposure to trade disruptions and tariff shifts.

Mergers, acquisitions, and licensing arrangements continue to shape capability portfolios, enabling companies to complement device offerings with consumables and services that drive recurring revenue streams. At the same time, corporate emphasis on training, remote servicing, and digital tools enhances product adoption and long-term customer retention. For purchasers and partners, the critical lens is alignment between clinical utility, total cost of ownership, and vendor commitments to evidence, support, and supply continuity.

Actionable recommendations for executives and clinical leaders to align evidence generation, supply diversification, pricing flexibility, and tailored adoption strategies for durable patient blood management success

Industry leaders should prioritize a coordinated approach that aligns clinical evidence generation with adaptive supply chain strategies and commercial models tailored to distinct care settings. Investing in rigorous clinical studies that demonstrate improvements in outcomes and procedural efficiency will help justify adoption of devices and therapies even in environments with constrained budgets. Equally important is the creation of flexible pricing and contracting options that reflect total cost of ownership and enable hospitals to trial technologies with limited upfront commitment.

Operationally, companies and provider networks should accelerate efforts to diversify manufacturing and distribution to mitigate tariff and logistics risks. Localization of production or strategic partnerships with regional manufacturers can lower exposure to cross-border disruptions and create cost advantages in competitive procurement processes. In parallel, building comprehensive training programs and remote-support ecosystems ensures that new technologies are implemented safely and effectively, driving clinician confidence and sustainable utilization.

Finally, aligning product development with end-user realities is paramount. Devices and disposables designed for ease of use in ambulatory and clinic environments will expand addressable markets, while modular systems that can scale for tertiary hospitals will meet demands of specialty centers. Cross-functional collaboration between clinical teams, procurement, and supplier account management will accelerate integration of PBM practices into standard care pathways and secure long-term value realization.

A transparent and rigorous research methodology combining expert interviews, clinical guideline synthesis, segmentation mapping, and validation workshops to underpin strategic insights without relying on proprietary market quantification

The research approach integrates multiple data streams and expert validation to ensure findings are robust, clinically relevant, and operationally actionable. Primary inputs include in-depth interviews with clinical leaders across cardiac surgery, trauma, oncology, and obstetrics, as well as discussions with procurement specialists, biomedical engineers, and senior hospital administrators to capture cross-functional perspectives on adoption drivers and barriers. These qualitative insights are triangulated with secondary literature, clinical guidelines, regulatory documents, and peer-reviewed studies to validate clinical assertions and technology performance.

Analytical rigor is maintained through structured segmentation mapping across product, therapy, application, and end-user dimensions, enabling consistent comparison of technology fit and adoption criteria. Validation workshops with clinical experts and supply chain professionals help refine assumptions and contextualize regional nuances. Data integrity is further strengthened by reconciling manufacturer product specifications with real-world usage patterns and by reviewing case studies that illustrate implementation challenges and success factors.

Ethical considerations and methodological transparency are upheld through clear documentation of inclusion criteria for expert interviews, anonymization protocols, and a replicable framework for categorizing technologies and therapies. The result is a methodologically sound synthesis that balances qualitative depth with cross-referenced evidence, equipping readers with a defensible basis for strategic decisions without relying on proprietary market quantifications.

A conclusive synthesis affirming that integrating clinical innovation, procurement agility, and supply resilience is essential to realize the full potential of patient blood management across care environments

Synthesis of the preceding insights underscores a clear strategic imperative: patient blood management is no longer an ancillary clinical concern but a core component of perioperative excellence, supply chain resilience, and value-based care. Advancements in autotransfusion, coagulation monitoring, hemostatic agents, and disposables are enabling clinicians to reduce reliance on allogeneic transfusion and to tailor interventions to individual patient risk profiles. At the same time, procurement leaders and manufacturers must navigate tariff-related pressures, supply chain realignment, and the need for compelling clinical evidence to sustain adoption.

Looking ahead, success in PBM will hinge on the ability of stakeholders to integrate clinical innovation with pragmatic commercial and operational strategies. Hospitals and specialty centers that prioritize preoperative optimization, invest in point-of-care capabilities, and foster multidisciplinary PBM programs will be better positioned to improve outcomes and manage resource constraints. Manufacturers and suppliers that align product design with diverse care settings, commit to robust evidence generation, and strengthen regional supply channels will capture enduring demand and support long-term clinical adoption.

Ultimately, the collective focus on patient safety, outcome transparency, and resilient supply chains will determine how effectively PBM innovations translate into routine clinical practice. Stakeholders that act decisively to bridge clinical priorities with procurement flexibility and operational preparedness will create measurable advantages in quality, safety, and institutional readiness.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Patient Blood Management Market, by Product Type

  • 8.1. Antifibrinolytics
  • 8.2. Autotransfusion Systems
  • 8.3. Blood Component Separation Systems
  • 8.4. Blood Management Disposables
    • 8.4.1. Cell Washing Kits
    • 8.4.2. Collection Reservoirs
    • 8.4.3. Filtration Devices
  • 8.5. Coagulation Monitoring Systems
    • 8.5.1. Laboratory Analyzers
    • 8.5.2. Point Of Care Devices
  • 8.6. Hemostats And Sealants
    • 8.6.1. Sealant Systems
    • 8.6.2. Topical Hemostats
  • 8.7. Volume Expanders

9. Patient Blood Management Market, by Therapy Type

  • 9.1. Allogeneic Transfusion
  • 9.2. Autologous Transfusion
  • 9.3. Cell Salvage
  • 9.4. Hemostasis Management
    • 9.4.1. Antifibrinolytic Therapy
    • 9.4.2. Topical Hemostats Therapy
  • 9.5. Perioperative Blood Conservation
    • 9.5.1. Intraoperative Techniques
    • 9.5.2. Postoperative Care
    • 9.5.3. Preoperative Optimization

10. Patient Blood Management Market, by Application

  • 10.1. Cardiovascular Surgery
    • 10.1.1. Aortic Surgery
    • 10.1.2. Coronary Artery Bypass Grafting
    • 10.1.3. Valve Replacement Procedures
  • 10.2. Elective Surgery
  • 10.3. Obstetrics
  • 10.4. Oncology Treatments
    • 10.4.1. Chemotherapy
    • 10.4.2. Radiotherapy
  • 10.5. Trauma

11. Patient Blood Management Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Hospitals
  • 11.4. Specialty Centers
    • 11.4.1. Cancer Treatment Centers
    • 11.4.2. Cardiac Care Centers
    • 11.4.3. Trauma Centers

12. Patient Blood Management Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Patient Blood Management Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Patient Blood Management Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Patient Blood Management Market

16. China Patient Blood Management Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Baxter International Inc.
  • 17.6. BioMerieux SA
  • 17.7. CSL Limited
  • 17.8. Danaher Corporation
  • 17.9. Fresenius Kabi AG
  • 17.10. Grifols, S.A.
  • 17.11. Haemonetics Corporation
  • 17.12. LivaNova PLC
  • 17.13. Macopharma SA
  • 17.14. Octapharma AG
  • 17.15. Roche Diagnostics International AG
  • 17.16. Terumo Corporation
  • 17.17. ZOLL Medical Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PATIENT BLOOD MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PATIENT BLOOD MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PATIENT BLOOD MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOTRANSFUSION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOTRANSFUSION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOTRANSFUSION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD COMPONENT SEPARATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD COMPONENT SEPARATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD COMPONENT SEPARATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL WASHING KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL WASHING KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL WASHING KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COLLECTION RESERVOIRS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COLLECTION RESERVOIRS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COLLECTION RESERVOIRS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY FILTRATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY FILTRATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY FILTRATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY LABORATORY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY LABORATORY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY LABORATORY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POINT OF CARE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POINT OF CARE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POINT OF CARE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SEALANT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SEALANT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SEALANT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VOLUME EXPANDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VOLUME EXPANDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VOLUME EXPANDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ALLOGENEIC TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ALLOGENEIC TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ALLOGENEIC TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOLOGOUS TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOLOGOUS TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AUTOLOGOUS TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL SALVAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL SALVAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CELL SALVAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ANTIFIBRINOLYTIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TOPICAL HEMOSTATS THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY INTRAOPERATIVE TECHNIQUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY INTRAOPERATIVE TECHNIQUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY INTRAOPERATIVE TECHNIQUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POSTOPERATIVE CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POSTOPERATIVE CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY POSTOPERATIVE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PREOPERATIVE OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AORTIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AORTIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AORTIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VALVE REPLACEMENT PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VALVE REPLACEMENT PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY VALVE REPLACEMENT PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ELECTIVE SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ELECTIVE SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ELECTIVE SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY OBSTETRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY OBSTETRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY OBSTETRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIAC CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIAC CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIAC CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY TRAUMA CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL PATIENT BLOOD MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 256. GCC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. GCC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. GCC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2032 (USD MILLION)
  • TABLE 259. GCC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 260. GCC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. GCC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 263. GCC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2018-2032 (USD MILLION)
  • TABLE 264. GCC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. GCC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 266. GCC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 267. GCC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. GCC PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COAGULATION MONITORING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTATS AND SEALANTS, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY HEMOSTASIS MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PERIOPERATIVE BLOOD CONSERVATION, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY ONCOLOGY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS PATIENT BLOOD MANAGEMENT MARKET SIZE, BY SPECIALTY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 295. G7 PATIENT BLOOD MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 296. G7 PATIENT BLOOD MANAGEMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. G7 PATIENT BLOOD MANAGEMENT MARKET SIZE, BY BLOOD MANAGEMENT DISPOSABLES, 2018-2032 (US